Entropy Technologies LP Acquires $6.48M Stake in Bristol Myers Squibb

The institutional investor bought 143,691 shares of the biopharmaceutical company's stock.

Mar. 13, 2026 at 9:09am

Got story updates? Submit your updates here. ›

Entropy Technologies LP, an institutional investor, has acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY) worth approximately $6.48 million. The investor purchased 143,691 shares of the biopharmaceutical company's stock during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission.

Why it matters

This investment highlights continued institutional interest in Bristol Myers Squibb, a major player in the biopharmaceutical industry. The company's stock has seen increased activity and valuation in recent quarters as it advances its pipeline of cancer and immune-mediated therapies.

The details

Entropy Technologies LP, a hedge fund, established the new position in Bristol Myers Squibb during the third quarter of 2026. The 143,691 shares acquired are valued at around $6.48 million based on the company's current stock price. Bristol Myers Squibb is a global biopharmaceutical firm focused on discovering, developing and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

  • Entropy Technologies LP bought the new stake in Bristol Myers Squibb in the 3rd quarter of 2026.
  • The 13F filing disclosing the investment was published on March 13, 2026.

The players

Entropy Technologies LP

An institutional investor and hedge fund that acquired a new stake in Bristol Myers Squibb.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

Got photos? Submit your photos here. ›

The takeaway

This investment by Entropy Technologies LP reflects ongoing institutional interest in Bristol Myers Squibb as the company continues to advance its pipeline of innovative therapies for cancer and other serious diseases. The stake acquisition highlights the biopharmaceutical firm's position as a leader in its field.